published meta-analysis   sensitivity analysis   studies

potential COVID-19 treatments in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias 14-days deathsdetailed resultsVERU-111, 2022 0.30 [0.14; 0.64] 0.30[0.14; 0.64]VERU-111, 202210%150NAnot evaluable death D28detailed resultsACTT-2 (Kalil), 2020 0.65 [0.39; 1.09] Aman, 2021 0.51 [0.27; 0.96] Bennett-Guerrero, 2021 0.86 [0.24; 3.11] Cadegiani, 2021 0.22 [0.16; 0.31] CAN-COVID, 2020 0.67 [0.30; 1.50] CONTAIN COVID-19, 2021 0.86 [0.60; 1.25] COV-BARRIER, 2021 0.57 [0.41; 0.79] COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95] COVACTA (Rosas), 2020 1.02 [0.62; 1.68] Fragoso-Saavedra (PISCO), 2020 0.32 [0.13; 0.80] Gharebaghi, 2020 0.00 [0.00; 0.09] Gunst JD, 2021 0.99 [0.29; 3.42] HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] ITAC, 2022 0.80 [0.42; 1.52] Kalil (ACTT-3), 2021 1.74 [0.51; 5.93] Lanzoni, 2021 0.14 [0.02; 0.96] Metcovid, 2020 0.92 [0.67; 1.28] Mobarak (DISCOVER), 2021 1.15 [0.83; 1.59] Mobarak S (DISCOVER), 2021 1.10 [0.77; 1.57] NCT04377750 (HMO-0224-20), 0 0.48 [0.15; 1.55] NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72] NIH NIAID ACTT-1, 2020 0.73 [0.52; 1.03] O’Donnell, 2021 0.47 [0.21; 1.06] PLACO-COVID, 2021 1.71 [0.72; 4.06] PlasmAr, 2020 0.93 [0.47; 1.85] Rosas (REMDACTA), 2021 0.95 [0.65; 1.39] Shi, 2020 0.53 [0.01; 27.55] Silva, 2021 0.46 [0.03; 8.02] Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18] Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92] STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62] Tang X, 2020 0.98 [0.93; 1.02] University of Minnesota, 2020 1.29 [0.51; 3.26] Zhang, 2020 0.50 [0.17; 1.50] 0.71[0.60; 0.85]ACTT-2 (Kalil), 2020, Aman, 2021, Bennett-Guerrero, 2021, Cadegiani, 2021, CAN-COVID, 2020, CONTAIN COVID-19, 2021, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Fragoso-Saavedra (PISCO), 2020, Gharebaghi, 2020, Gunst JD, 2021, HYDRA (Hernandez-Cardenas), 2021, ITAC, 2022, Kalil (ACTT-3), 2021, Lanzoni, 2021, Metcovid, 2020, Mobarak (DISCOVER), 2021, Mobarak S (DISCOVER), 2021, NCT04377750 (HMO-0224-20), 0, NCT04412772 (ARCHITECTS), 0, NIH NIAID ACTT-1, 2020, O’Donnell, 2021, PLACO-COVID, 2021, PlasmAr, 2020, Rosas (REMDACTA), 2021, Shi, 2020, Silva, 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, STOP-COVID (Guimarães), 2021, Tang X, 2020, University of Minnesota, 2020, Zhang, 20203575%14,835moderatecritical death or transfer to ICUdetailed resultsBACC Bay Tocilizumab Trial, 2020 0.97 [0.50; 1.88] COLCHIVID, 2021 0.83 [0.35; 1.95] Gunst JD, 2021 0.55 [0.26; 1.17] Lopardo, 2021 0.65 [0.35; 1.22] 0.73[0.51; 1.05]BACC Bay Tocilizumab Trial, 2020, COLCHIVID, 2021, Gunst JD, 2021, Lopardo, 202140%688lownot evaluable deathsdetailed resultsACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17] ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97] ACTIV-3/TICO LY-CoV555 , 2020 1.71 [0.56; 5.21] ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09] Aman, 2021 0.51 [0.27; 0.96] BACC Bay Tocilizumab Trial, 2020 1.52 [0.41; 5.62] Baldeon, 2022 1.85 [0.49; 6.97] Bennett-Guerrero, 2021 0.80 [0.26; 2.45] Cadegiani, 2021 0.16 [0.11; 0.24] CAN-COVID, 2020 0.67 [0.30; 1.50] CAP-China (Wang et al.), 2020 1.10 [0.49; 2.45] CAPE-COVID, 2020 0.45 [0.20; 1.02] CCAP-2, 2021 2.03 [0.61; 6.77] COLCHIVID, 2021 0.69 [0.20; 2.40] CONTAIN COVID-19, 2021 0.86 [0.60; 1.25] COV-BARRIER, 2021 0.57 [0.41; 0.79] COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95] COVACTA (Rosas), 2020 1.16 [0.73; 1.84] CPC-SARS, 2021 0.04 [0.01; 0.26] DEVENT, 0 0.47 [0.22; 1.00] EMPACTA, 2020 1.13 [0.54; 2.40] Fragoso-Saavedra (PISCO), 2020 0.33 [0.14; 0.79] Gharebaghi, 2020 0.00 [0.00; 0.09] Gonzalez (HCQ), 2020 0.33 [0.06; 1.78] Gonzalez (IVER), 2020 0.83 [0.23; 3.02] Gunst JD, 2021 0.70 [0.20; 2.49] HYCOVID, 2020 0.54 [0.21; 1.40] HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] ILBS-COVID-02 (Bajpai M), 2020 3.82 [0.35; 41.96] ITAC, 2022 0.80 [0.42; 1.52] Kalil (ACTT-3), 2021 1.74 [0.51; 5.93] Kirti, 2021 0.12 [0.01; 2.36] LACCPT, 2021 1.17 [0.58; 2.36] Lanzoni, 2021 0.11 [0.01; 0.93] Lescure (Sarilumab 200mg), 2021 1.23 [0.49; 3.12] Lescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50] Libster, 2020 0.50 [0.09; 2.71] LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21] Lopardo, 2021 0.57 [0.24; 1.37] Lopes MIF, 2020 1.06 [0.02; 56.61] Metcovid, 2020 0.92 [0.67; 1.28] Mobarak (DISCOVER), 2021 1.15 [0.83; 1.59] Mobarak S (DISCOVER), 2021 1.15 [0.80; 1.67] Murai, 2020 1.53 [0.53; 4.43] NCT04342650, 2020 0.95 [0.02; 48.42] NCT04377750 (HMO-0224-20), 0 0.48 [0.15; 1.55] NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72] NCT04442191, 2021 0.11 [0.00; 143.68] NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84] ORCHID, 2020 1.07 [0.54; 2.11] O’Donnell, 2021 0.47 [0.21; 1.06] Patel, 2021 0.77 [0.11; 5.34] PLACO-COVID, 2021 1.71 [0.72; 4.06] PlasmAr, 2020 0.93 [0.47; 1.85] ProPAC-COVID, 2021 0.08 [0.00; 8.65] RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47] Rocco, 2020 1.02 [0.02; 51.70] Rosas (REMDACTA), 2021 0.95 [0.65; 1.39] Salehzadeh, 2020 1.00 [0.02; 51.41] sarilumab phase 2 high dose, 0 0.78 [0.34; 1.80] sarimulab phase 2 low dose, 0 1.51 [0.69; 3.32] SAVE-MORE, 2021 0.45 [0.20; 0.99] Shenoy S, 2021 1.32 [0.58; 2.99] Shi, 2020 0.53 [0.01; 27.55] Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18] Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92] SPRINTER, 2022 0.79 [0.38; 1.66] STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62] Synairgen SG016, 2020 0.16 [0.01; 3.31] Tang X, 2020 0.98 [0.93; 1.02] TEACH, 2020 1.07 [0.34; 3.37] University of Minnesota, 2020 0.68 [0.11; 4.16] Zhang, 2020 0.50 [0.17; 1.50] 0.75[0.66; 0.85]ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, ACTT-2 (Kalil), 2020, Aman, 2021, BACC Bay Tocilizumab Trial, 2020, Baldeon, 2022, Bennett-Guerrero, 2021, Cadegiani, 2021, CAN-COVID, 2020, CAP-China (Wang et al.), 2020, CAPE-COVID, 2020, CCAP-2, 2021, COLCHIVID, 2021, CONTAIN COVID-19, 2021, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, CPC-SARS, 2021, DEVENT, 0, EMPACTA, 2020, Fragoso-Saavedra (PISCO), 2020, Gharebaghi, 2020, Gonzalez (HCQ), 2020, Gonzalez (IVER), 2020, Gunst JD, 2021, HYCOVID, 2020, HYDRA (Hernandez-Cardenas), 2021, ILBS-COVID-02 (Bajpai M), 2020, ITAC, 2022, Kalil (ACTT-3), 2021, Kirti, 2021, LACCPT, 2021, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Libster, 2020, LIVE-AIR (Temesgen), 2021, Lopardo, 2021, Lopes MIF, 2020, Metcovid, 2020, Mobarak (DISCOVER), 2021, Mobarak S (DISCOVER), 2021, Murai, 2020, NCT04342650, 2020, NCT04377750 (HMO-0224-20), 0, NCT04412772 (ARCHITECTS), 0, NCT04442191, 2021, NIH NIAID ACTT-1, 2020, ORCHID, 2020, O’Donnell, 2021, Patel, 2021, PLACO-COVID, 2021, PlasmAr, 2020, ProPAC-COVID, 2021, RIVET-COV (Mohan) (12mg and 24mg), 2021, Rocco, 2020, Rosas (REMDACTA), 2021, Salehzadeh, 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, SAVE-MORE, 2021, Shenoy S, 2021, Shi, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, SPRINTER, 2022, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020, Tang X, 2020, TEACH, 2020, University of Minnesota, 2020, Zhang, 20207462%24,095moderatecritical deaths (time to event analysis only)detailed resultsACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17] ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97] ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09] Baldeon, 2022 1.85 [0.49; 6.97] Bennett-Guerrero, 2021 0.80 [0.26; 2.45] Cadegiani, 2021 0.16 [0.11; 0.24] COV-BARRIER, 2021 0.57 [0.41; 0.79] COVACTA (Rosas), 2020 1.16 [0.73; 1.84] Fragoso-Saavedra (PISCO), 2020 0.33 [0.14; 0.79] Gunst JD, 2021 0.70 [0.20; 2.49] HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] Kalil (ACTT-3), 2021 1.74 [0.51; 5.93] Lanzoni, 2021 0.11 [0.01; 0.93] LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21] NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84] PlasmAr, 2020 0.93 [0.47; 1.85] Rosas (REMDACTA), 2021 0.95 [0.65; 1.39] Zhang, 2020 0.50 [0.17; 1.50] 0.66[0.50; 0.89]ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022, ACTT-2 (Kalil), 2020, Baldeon, 2022, Bennett-Guerrero, 2021, Cadegiani, 2021, COV-BARRIER, 2021, COVACTA (Rosas), 2020, Fragoso-Saavedra (PISCO), 2020, Gunst JD, 2021, HYDRA (Hernandez-Cardenas), 2021, Kalil (ACTT-3), 2021, Lanzoni, 2021, LIVE-AIR (Temesgen), 2021, NIH NIAID ACTT-1, 2020, PlasmAr, 2020, Rosas (REMDACTA), 2021, Zhang, 20201877%9,845moderatelow clinical deteriorationdetailed resultsBACC Bay Tocilizumab Trial, 2020 1.11 [0.59; 2.09] CAP-China (Wang et al.), 2020 0.95 [0.55; 1.64] CONTAIN COVID-19, 2021 0.94 [0.75; 1.18] COV-BARRIER, 2021 1.12 [0.58; 2.16] EMPACTA, 2020 0.55 [0.33; 0.92] Libster, 2020 0.52 [0.29; 0.94] RIVET-COV (Mohan) (12mg and 24mg), 2021 0.53 [0.15; 1.95] Rocco, 2020 1.02 [0.29; 3.58] SAVE-MORE, 2021 0.36 [0.26; 0.50] SPRINTER, 2022 0.69 [0.43; 1.11] STOP-COVID (Guimarães), 2021 0.54 [0.27; 1.07] Synairgen SG016, 2020 0.50 [0.18; 1.38] Tang X, 2020 1.00 [0.13; 7.45] TEACH, 2020 1.80 [0.62; 5.21] Zhang, 2020 0.40 [0.10; 1.65] 0.71[0.55; 0.91]BACC Bay Tocilizumab Trial, 2020, CAP-China (Wang et al.), 2020, CONTAIN COVID-19, 2021, COV-BARRIER, 2021, EMPACTA, 2020, Libster, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Rocco, 2020, SAVE-MORE, 2021, SPRINTER, 2022, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020, Tang X, 2020, TEACH, 2020, Zhang, 20201560%4,616lowlow clinical improvementdetailed resultsACTIV-3/TICO (tixa), 2022 1.08 [0.97; 1.20] ACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29] ACTT-2 (Kalil), 2020 1.16 [1.01; 1.33] BACC Bay Tocilizumab Trial, 2020 1.06 [0.80; 1.41] Bennett-Guerrero, 2021 0.75 [0.21; 2.68] Cadegiani, 2021 2.28 [1.95; 2.66] CAN-COVID, 2020 1.39 [0.76; 2.54] CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74] COV-BARRIER, 2021 1.25 [1.04; 1.50] COV-BARRIER (critically ill), 2022 2.87 [1.12; 7.36] COVACTA (Rosas), 2020 1.19 [0.81; 1.75] EMPACTA, 2020 1.15 [0.90; 1.47] Gunst JD, 2021 1.14 [0.83; 1.57] ITAC, 2022 1.06 [0.77; 1.45] Kalil (ACTT-3), 2021 0.99 [0.87; 1.13] Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41] Lopardo, 2021 1.61 [0.75; 3.49] NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49] ORCHID, 2020 1.02 [0.73; 1.42] O’Donnell, 2021 1.20 [0.87; 1.65] PlasmAr, 2020 0.81 [0.50; 1.31] Rocco, 2020 0.81 [0.52; 1.27] sarilumab phase 2 high dose, 0 2.09 [1.00; 4.36] sarimulab phase 2 low dose, 0 1.51 [0.73; 3.11] Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60] Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25] Synairgen SG016, 2020 2.32 [1.07; 5.04] Tang X, 2020 1.04 [0.67; 1.62] 1.20[1.07; 1.34]ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, ACTT-2 (Kalil), 2020, BACC Bay Tocilizumab Trial, 2020, Bennett-Guerrero, 2021, Cadegiani, 2021, CAN-COVID, 2020, CAP-China (Wang et al.), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, EMPACTA, 2020, Gunst JD, 2021, ITAC, 2022, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Lopardo, 2021, NIH NIAID ACTT-1, 2020, ORCHID, 2020, O’Donnell, 2021, PlasmAr, 2020, Rocco, 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Synairgen SG016, 2020, Tang X, 20202873%11,592moderatelow clinical improvement (14-day)detailed resultsACTT-2 (Kalil), 2020 1.30 [1.03; 1.64] Cadegiani, 2021 2.28 [1.95; 2.66] CAP-China (Wang et al.), 2020 1.21 [0.64; 2.28] COV-BARRIER, 2021 1.28 [1.05; 1.56] COV-BARRIER (critically ill), 2022 1.97 [0.95; 4.09] Kalil (ACTT-3), 2021 1.01 [0.79; 1.29] ORCHID, 2020 1.02 [0.73; 1.42] Tang X, 2020 1.33 [0.57; 3.11] 1.36[1.03; 1.80]ACTT-2 (Kalil), 2020, Cadegiani, 2021, CAP-China (Wang et al.), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, Kalil (ACTT-3), 2021, ORCHID, 2020, Tang X, 2020886%5,074moderatenot evaluable clinical improvement (28-day)detailed resultsBennett-Guerrero, 2021 1.02 [0.25; 4.20] Cadegiani, 2021 1.81 [1.60; 2.05] CAP-China (Wang et al.), 2020 1.37 [0.79; 2.39] COV-BARRIER (critically ill), 2022 1.82 [0.87; 3.81] COVACTA (Rosas), 2020 1.19 [0.81; 1.75] NIH NIAID ACTT-1, 2020 1.35 [1.03; 1.76] ORCHID, 2020 0.97 [0.69; 1.37] O’Donnell, 2021 1.38 [0.73; 2.61] Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60] Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25] Synairgen SG016, 2020 3.15 [1.39; 7.14] 1.45[1.18; 1.77]Bennett-Guerrero, 2021, Cadegiani, 2021, CAP-China (Wang et al.), 2020, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, NIH NIAID ACTT-1, 2020, ORCHID, 2020, O’Donnell, 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Synairgen SG016, 20201149%3,384moderatelow clinical improvement (7-day)detailed resultsACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29] CAP-China (Wang et al.), 2020 0.99 [0.18; 5.51] ITAC, 2022 1.06 [0.77; 1.45] Kirti, 2021 0.90 [0.77; 1.06] ORCHID, 2020 1.16 [0.84; 1.61] Rocco, 2020 0.81 [0.52; 1.27] 0.94[0.84; 1.06]ACTIV-3/TICO LY-CoV555 , 2020, CAP-China (Wang et al.), 2020, ITAC, 2022, Kirti, 2021, ORCHID, 2020, Rocco, 202060%2,118moderatenot evaluable clinical improvement (time to event analysis only)detailed resultsACTT-2 (Kalil), 2020 1.16 [1.01; 1.33] Bennett-Guerrero, 2021 0.75 [0.21; 2.68] CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74] EMPACTA, 2020 1.15 [0.90; 1.47] Gunst JD, 2021 1.14 [0.83; 1.57] HYDRA (Hernandez-Cardenas), 2021 1.05 [0.74; 1.48] Kalil (ACTT-3), 2021 0.99 [0.87; 1.13] Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41] Lescure (Sarilumab 400mg), 2021 1.14 [0.84; 1.54] NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49] ORCHID, 2020 0.97 [0.69; 1.36] O’Donnell, 2021 1.20 [0.87; 1.65] PlasmAr, 2020 1.00 [0.76; 1.32] sarimulab phase 2 low dose, 0 0.96 [0.53; 1.73] Shenoy S, 2021 0.99 [0.77; 1.28] Shinkai, 2021 1.40 [0.91; 2.15] SPRINTER, 2022 1.02 [0.81; 1.28] Tang X, 2020 1.04 [0.67; 1.62] Wu X, 2020 2.00 [0.71; 5.66] 1.11[1.05; 1.17]ACTT-2 (Kalil), 2020, Bennett-Guerrero, 2021, CAP-China (Wang et al.), 2020, EMPACTA, 2020, Gunst JD, 2021, HYDRA (Hernandez-Cardenas), 2021, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, NIH NIAID ACTT-1, 2020, ORCHID, 2020, O’Donnell, 2021, PlasmAr, 2020, sarimulab phase 2 low dose, 0, Shenoy S, 2021, Shinkai, 2021, SPRINTER, 2022, Tang X, 2020, Wu X, 2020190%7,283moderatelow death or ventilationdetailed resultsACTT-2 (Kalil), 2020 0.69 [0.50; 0.95] BACC Bay Tocilizumab Trial, 2020 0.83 [0.38; 1.81] CAPE-COVID, 2020 0.71 [0.37; 1.35] EMPACTA, 2020 0.56 [0.32; 0.97] Fragoso-Saavedra (PISCO), 2020 0.46 [0.22; 0.96] Gonzalez (HCQ), 2020 0.69 [0.22; 2.21] Gonzalez (IVER), 2020 0.89 [0.30; 2.64] HYCOVID, 2020 1.12 [0.45; 2.79] LIVE-AIR (Temesgen), 2021 0.65 [0.43; 0.98] ORCHID, 2020 1.13 [0.60; 2.13] Rosas (REMDACTA), 2021 0.98 [0.72; 1.34] sarilumab phase 2 high dose, 0 0.39 [0.18; 0.82] sarimulab phase 2 low dose, 0 0.70 [0.34; 1.44] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.66 [0.46; 0.94] SPRINTER, 2022 0.85 [0.45; 1.61] STOP-COVID (Guimarães), 2021 0.63 [0.41; 0.97] Synairgen SG016, 2020 0.38 [0.09; 1.63] 0.72[0.63; 0.82]ACTT-2 (Kalil), 2020, BACC Bay Tocilizumab Trial, 2020, CAPE-COVID, 2020, EMPACTA, 2020, Fragoso-Saavedra (PISCO), 2020, Gonzalez (HCQ), 2020, Gonzalez (IVER), 2020, HYCOVID, 2020, LIVE-AIR (Temesgen), 2021, ORCHID, 2020, Rosas (REMDACTA), 2021, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, SPRINTER, 2022, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020170%5,507moderatelow hospital dischargedetailed resultsACTIV-3/TICO LY-CoV555 , 2020 0.97 [0.78; 1.20] CAPE-COVID, 2020 1.67 [0.87; 3.19] COLCHIVID, 2021 1.13 [0.76; 1.67] EMPACTA, 2020 1.16 [0.90; 1.49] Fragoso-Saavedra (PISCO), 2020 1.13 [0.82; 1.55] Gonzalez (HCQ), 2020 1.38 [0.46; 4.16] Gonzalez (IVER), 2020 0.71 [0.15; 3.40] HYDRA (Hernandez-Cardenas), 2021 1.01 [0.72; 1.42] Kirti, 2021 1.20 [0.73; 1.98] Mobarak (DISCOVER), 2021 1.01 [0.95; 1.08] Murai, 2020 0.99 [0.71; 1.38] Patel, 2021 0.57 [0.12; 2.68] RIVET-COV (Mohan) (12mg and 24mg), 2021 2.31 [0.66; 8.04] Rosas (REMDACTA), 2021 0.97 [0.79; 1.20] Shenoy S, 2021 1.06 [0.85; 1.32] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1.48 [1.05; 2.09] SPRINTER, 2022 1.06 [0.89; 1.27] Synairgen SG016, 2020 1.63 [0.61; 4.35] University of Minnesota, 2020 0.64 [0.37; 1.11] 1.03[0.98; 1.08]ACTIV-3/TICO LY-CoV555 , 2020, CAPE-COVID, 2020, COLCHIVID, 2021, EMPACTA, 2020, Fragoso-Saavedra (PISCO), 2020, Gonzalez (HCQ), 2020, Gonzalez (IVER), 2020, HYDRA (Hernandez-Cardenas), 2021, Kirti, 2021, Mobarak (DISCOVER), 2021, Murai, 2020, Patel, 2021, RIVET-COV (Mohan) (12mg and 24mg), 2021, Rosas (REMDACTA), 2021, Shenoy S, 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, SPRINTER, 2022, Synairgen SG016, 2020, University of Minnesota, 2020190%6,282lowlow hospitalizationdetailed resultsEPIC-SR, 0 0.29 [0.08; 1.07] Holubar M, 2021 0.12 [0.01; 2.26] Jagannathan, 2020 1.00 [0.14; 7.34] University of Minnesota, 2020 1.63 [0.94; 2.85] 0.67[0.20; 2.17]EPIC-SR, 0, Holubar M, 2021, Jagannathan, 2020, University of Minnesota, 2020463%1,328lownot evaluable mechanical ventilationdetailed resultsACTT-2 (Kalil), 2020 0.64 [0.44; 0.93] Cadegiani, 2021 0.10 [0.04; 0.29] CAPE-COVID, 2020 0.95 [0.44; 2.04] COVACTA (Rosas), 2020 0.67 [0.39; 1.14] Fragoso-Saavedra (PISCO), 2020 0.85 [0.27; 2.62] Gunst JD, 2021 2.27 [0.62; 8.26] Kirti, 2021 0.20 [0.00; 8.69] Metcovid, 2020 1.19 [0.56; 2.49] Mobarak S (DISCOVER), 2021 1.52 [0.72; 3.19] Murai, 2020 0.49 [0.21; 1.14] O’Donnell, 2021 1.50 [0.47; 4.82] PlasmAr, 2020 0.86 [0.39; 1.93] RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47] sarilumab phase 2 high dose, 0 0.27 [0.10; 0.71] sarimulab phase 2 low dose, 0 0.28 [0.11; 0.73] SAVE-MORE, 2021 0.47 [0.03; 7.48] Singh (TD-0903 1mg), 2021 0.09 [0.00; 2.48] Singh (TD-0903 3mg), 2021 0.08 [0.00; 2.07] University of Minnesota, 2020 1.34 [0.66; 2.73] 0.68[0.48; 0.95]ACTT-2 (Kalil), 2020, Cadegiani, 2021, CAPE-COVID, 2020, COVACTA (Rosas), 2020, Fragoso-Saavedra (PISCO), 2020, Gunst JD, 2021, Kirti, 2021, Metcovid, 2020, Mobarak S (DISCOVER), 2021, Murai, 2020, O’Donnell, 2021, PlasmAr, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, SAVE-MORE, 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, University of Minnesota, 20201955%5,913moderatelow mechanical ventilation (time to event analysis only)detailed resultsFragoso-Saavedra (PISCO), 2020 0.81 [0.27; 2.42] Gunst JD, 2021 0.69 [0.14; 3.42] 0.77[0.31; 1.90]Fragoso-Saavedra (PISCO), 2020, Gunst JD, 202120%396moderatenot evaluable Recovery (time to event analysis only)detailed resultsSPRINTER, 2022 1.02 [0.81; 1.28] 1.02[0.81; 1.28]SPRINTER, 202210%623NAnot evaluable viral clearance detailed resultsChaccour, 2020 0.92 [0.77; 1.09] Holubar M, 2021 0.76 [0.48; 1.20] Jagannathan, 2020 0.81 [0.56; 1.18] Rastogi, 2020 6.33 [1.54; 26.00] RIVET-COV (Mohan) (12mg and 24mg), 2021 1.10 [0.50; 2.39] Tang X, 2020 1.78 [1.06; 3.00] 1.07[0.78; 1.48]Chaccour, 2020, Holubar M, 2021, Jagannathan, 2020, Rastogi, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Tang X, 2020665%533lownot evaluable viral clearance (time to event analysis only)detailed resultsAhmed, 2020 4.10 [1.12; 14.99] Holubar M, 2021 0.76 [0.48; 1.20] Jagannathan, 2020 0.81 [0.56; 1.18] Tang X, 2020 1.78 [1.06; 3.00] 1.20[0.69; 2.08]Ahmed, 2020, Holubar M, 2021, Jagannathan, 2020, Tang X, 2020475%427moderatenot evaluable viral clearance by day 14detailed resultsAhmed, 2020 4.10 [1.12; 14.99] 4.10[1.12; 14.99]Ahmed, 202010%72NAnot evaluable viral clearance by day 7detailed resultsChaccour, 2020 0.92 [0.77; 1.09] Kirti, 2021 0.80 [0.43; 1.50] RIVET-COV (Mohan) (12mg and 24mg), 2021 1.10 [0.50; 2.39] 0.92[0.78; 1.08]Chaccour, 2020, Kirti, 2021, RIVET-COV (Mohan) (12mg and 24mg), 202130%250lownot evaluable ICU admissiondetailed resultsCOVACTA (Rosas), 2020 0.48 [0.25; 0.94] Gunst JD, 2021 0.80 [0.34; 1.90] Kirti, 2021 0.90 [0.30; 2.70] Libster, 2020 0.33 [0.07; 1.58] Lopardo, 2021 0.67 [0.35; 1.28] Lopes MIF, 2020 1.06 [0.06; 18.45] Murai, 2020 0.71 [0.37; 1.37] ProPAC-COVID, 2021 1.24 [0.26; 5.80] Rocco, 2020 4.11 [0.18; 91.83] Tang X, 2020 1.00 [0.13; 7.45] 0.68[0.50; 0.93]COVACTA (Rosas), 2020, Gunst JD, 2021, Kirti, 2021, Libster, 2020, Lopardo, 2021, Lopes MIF, 2020, Murai, 2020, ProPAC-COVID, 2021, Rocco, 2020, Tang X, 2020100%1,776moderatelow off oxygenationdetailed resultsHYDRA (Hernandez-Cardenas), 2021 0.98 [0.64; 1.51] ILBS-COVID-02 (Bajpai M), 2020 0.26 [0.02; 2.88] sarilumab phase 2 high dose, 0 1.99 [0.95; 4.15] sarimulab phase 2 low dose, 0 1.07 [0.52; 2.21] 1.15[0.74; 1.77]HYDRA (Hernandez-Cardenas), 2021, ILBS-COVID-02 (Bajpai M), 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0428%513seriousnot evaluable recoverydetailed resultsACTIV-3 (BRII-196 and BRII-198), 2021 1.08 [0.88; 1.32] ACTIV-3/ TICO (sotrovimab), 2021 1.12 [0.91; 1.37] ACTIV-3/TICO LY-CoV555 , 2020 1.06 [0.77; 1.46] COV-BARRIER (critically ill), 2022 1.57 [0.77; 3.20] Crippa (CANDIDATE), 2021 0.54 [0.15; 1.94] Gunst JD, 2021 1.18 [0.87; 1.61] Lanzoni, 2021 3.46 [1.05; 11.35] Mobarak S (DISCOVER), 2021 0.97 [0.89; 1.05] Synairgen SG016, 2020 2.19 [1.03; 4.67] 1.10[0.97; 1.26]ACTIV-3 (BRII-196 and BRII-198), 2021, ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO LY-CoV555 , 2020, COV-BARRIER (critically ill), 2022, Crippa (CANDIDATE), 2021, Gunst JD, 2021, Lanzoni, 2021, Mobarak S (DISCOVER), 2021, Synairgen SG016, 2020942%2,636lowserious AE leading to drug discontinuationdetailed resultsCAP-China (Wang et al.), 2020 2.43 [0.79; 7.45] 2.43[0.79; 7.45]CAP-China (Wang et al.), 202010%233NAnot evaluable composite safety outcome detailed resultsACTIV-3/TICO LY-CoV555 , 2020 1.56 [0.78; 3.11] 1.56[0.78; 3.11]ACTIV-3/TICO LY-CoV555 , 202010%314NAnot evaluable related AE (TRAE)detailed resultsSingh (TD-0903 1mg), 2021 2.50 [0.16; 38.60] Singh (TD-0903 3mg), 2021 0.38 [0.01; 13.93] 1.26[0.14; 11.07]Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 202120%25moderatenot evaluable serious adverse eventsdetailed resultsBACC Bay Tocilizumab Trial, 2020 1.21 [0.58; 2.53] CAN-COVID, 2020 0.73 [0.45; 1.19] CAP-China (Wang et al.), 2020 0.64 [0.33; 1.23] COVACTA (Rosas), 2020 0.81 [0.54; 1.22] Gunst JD, 2021 1.84 [0.79; 4.30] ITAC, 2022 0.98 [0.66; 1.46] Jagannathan, 2020 1.00 [0.14; 7.34] Lanzoni, 2021 0.10 [0.01; 0.69] Lescure (Sarilumab 200mg), 2021 1.15 [0.62; 2.12] Lescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51] Murai, 2020 0.99 [0.02; 50.39] NIH NIAID ACTT-1, 2020 0.72 [0.54; 0.96] ORCHID, 2020 1.26 [0.56; 2.84] O’Donnell, 2021 0.64 [0.35; 1.17] PlasmAr, 2020 1.40 [0.78; 2.51] RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47] Rosas (REMDACTA), 2021 0.83 [0.59; 1.18] Shi, 2020 1.08 [0.04; 32.96] Shinkai, 2021 2.80 [0.14; 56.95] 0.89[0.77; 1.04]BACC Bay Tocilizumab Trial, 2020, CAN-COVID, 2020, CAP-China (Wang et al.), 2020, COVACTA (Rosas), 2020, Gunst JD, 2021, ITAC, 2022, Jagannathan, 2020, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Murai, 2020, NIH NIAID ACTT-1, 2020, ORCHID, 2020, O’Donnell, 2021, PlasmAr, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Rosas (REMDACTA), 2021, Shi, 2020, Shinkai, 20211911%6,172moderatelow superinfectiondetailed resultsACTT-2 (Kalil), 2020 0.50 [0.32; 0.79] CAPE-COVID, 2020 0.81 [0.49; 1.34] Metcovid, 2020 0.98 [0.65; 1.47] 0.74[0.49; 1.11]ACTT-2 (Kalil), 2020, CAPE-COVID, 2020, Metcovid, 2020357%1,575lownot evaluable adverse eventsdetailed resultsChaccour, 2020 1.00 [0.20; 5.07] COLCHIVID, 2021 1.63 [0.67; 3.95] COVACTA (Rosas), 2020 0.87 [0.52; 1.45] Gunst JD, 2021 0.80 [0.43; 1.51] Holubar M, 2021 2.07 [0.89; 4.83] Jagannathan, 2020 1.33 [0.63; 2.78] Lanzoni, 2021 0.18 [0.02; 1.95] Lescure (Sarilumab 200mg), 2021 0.97 [0.56; 1.69] Lescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27] Murai, 2020 1.99 [0.07; 59.94] ORCHID, 2020 1.42 [0.87; 2.34] RIVET-COV (Mohan) (12mg and 24mg), 2021 1.25 [0.45; 3.47] Rosas (REMDACTA), 2021 1.32 [0.92; 1.89] Shi, 2020 0.88 [0.38; 2.03] Shinkai, 2021 19.54 [7.77; 49.11] Singh (TD-0903 1mg), 2021 0.45 [0.01; 16.71] Singh (TD-0903 3mg), 2021 0.04 [0.00; 1.01] TEACH, 2020 1.16 [0.55; 2.42] 1.31[0.94; 1.81]Chaccour, 2020, COLCHIVID, 2021, COVACTA (Rosas), 2020, Gunst JD, 2021, Holubar M, 2021, Jagannathan, 2020, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Murai, 2020, ORCHID, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Rosas (REMDACTA), 2021, Shi, 2020, Shinkai, 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, TEACH, 20201865%3,378moderatelow deep vein thrombosisdetailed resultsCAP-China (Wang et al.), 2020 0.50 [0.03; 8.10] NIH NIAID ACTT-1, 2020 0.64 [0.23; 1.81] 0.62[0.23; 1.64]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202020%1,296moderatenot evaluable elevated liver enzymesdetailed resultsCAP-China (Wang et al.), 2020 0.36 [0.13; 1.01] NIH NIAID ACTT-1, 2020 0.67 [0.38; 1.18] 0.58[0.34; 0.97]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202026%1,296moderatenot evaluable hyperbilirubinemiadetailed resultsCAP-China (Wang et al.), 2020 1.09 [0.42; 2.79] NIH NIAID ACTT-1, 2020 0.84 [0.30; 2.34] 0.97[0.48; 1.93]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202020%1,296lownot evaluable pulmonary embolismdetailed resultsCAP-China (Wang et al.), 2020 0.50 [0.03; 8.10] NIH NIAID ACTT-1, 2020 0.96 [0.19; 4.80] 0.82[0.20; 3.29]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202020%1,296moderatenot evaluable renal impairmentdetailed resultsCAP-China (Wang et al.), 2020 1.01 [0.03; 30.33] NIH NIAID ACTT-1, 2020 1.02 [0.64; 1.61] 1.02[0.64; 1.61]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202020%1,296moderatenot evaluable severe adverse eventsdetailed resultsPatel, 2021 1.21 [0.02; 64.67] 1.21[0.02; 64.67]Patel, 202110%33NAnot evaluable0.210.01.0relative treatment effectwww.metaEvidence.org2024-05-16 03:35 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439 - roots T: 290